Is Medicamen Organ. overvalued or undervalued?
As of October 10, 2025, Medicamen Organ. is considered overvalued with a valuation grade shift to expensive, reflected by a PE Ratio of 12.83, an EV to EBITDA of 9.15, and a -38.93% return over the past year, underperforming compared to peers like Sun Pharma and Dr. Reddy's Labs.
As of 10 October 2025, the valuation grade for Medicamen Organ. has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued based on its key financial ratios, which include a PE Ratio of 12.83, an EV to EBITDA of 9.15, and a ROE of 11.29%. In comparison to its peers, Medicamen Organ. stands out as expensive, particularly when juxtaposed with Sun Pharma, which has a significantly higher PE Ratio of 34.96, and Dr. Reddy's Labs, valued attractively with a PE Ratio of 18.58. Despite a recent uptick in stock price, Medicamen Organ. has underperformed the Sensex over the past year, with a return of -38.93% compared to the Sensex's modest gain of 1.15%. This combination of factors reinforces the conclusion that Medicamen Organ. is currently overvalued in the market.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
